Clinical Trials in Maryland

Showing 10161-10180 of 23,284 trials

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

NCT02996474

Background: Acute myeloid leukemia (AML) is a cancer of the white blood cells. It is fatal if not treated. Treatment for AML that has not responded to treatment (refractory) or has returned after treatment (relapsed) often do not work. Researchers want to see if an immunotherapy drug, combined with a less intense chemotherapy, may be able to help. Objective: To test if pembrolizumab, in combination with decitabine, is a possible treatment for people with relapsed or refractory AML. Eligibility: Adults 18 years of age and older with refractory AML or relapsed AML. Design: Participants will be first screened for eligibility. The study is counted in 21-day cycles. The initial phase of the study consists of 8 cycles. Participants may be in the study for up to 2 years if they are responding to the treatment. The first 3 weeks of treatment is usually done in the hospital. The rest may be done as an outpatient. Participants will get pembrolizumab at the beginning of each cycle through an IV. Participants will usually get decitabine by IV on days 8 12 and days 15 19 of every other cycle. Participants will give blood samples. Participants will have bone marrow exams. A needle will be inserted into the hip to extract cells from the bone marrow. Some participants may give a sample of saliva from the inside of their cheek. Some participants may give a small skin sample. The top layer of the skin is removed. Some patients may require leukapheresis before starting treatment. This is a procedure to remove leukemia cells in the blood stream.

Relapsed Acute Myeloid Leukemia

National Heart, Lung, and Blood Institute (NHLBI)10 participantsStarted Dec 2016

Bethesda, Maryland, United States

TERMINATEDPhase 1/217 miles

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

NCT02923531

The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.

Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals9 participantsStarted Dec 2016

Washington D.C., District of Columbia, United States • Boston, Massachusetts, United States • Hackensack, New Jersey, United States +1 more locations

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Find Trials by Condition in Maryland

REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Blood Flow Restriction Following ACL Reconstruction

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Evaluation of GLR2007 for Advanced Solid Tumors

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

Validation of Dyskinesia Rating Scales

OLAParib COmbinations

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics